These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 28062624)

  • 1. Plasma N-terminal Prosomatostatin and Risk of Incident Cardiovascular Disease and All-Cause Mortality in a Prospective Observational Cohort: the PREVEND Study.
    Abbasi A; Kieneker LM; Corpeleijn E; Gansevoort RT; Gans RO; Struck J; de Boer RA; Hillege HL; Stolk RP; Navis G; Bakker SJ
    Clin Chem; 2017 Jan; 63(1):278-287. PubMed ID: 28062624
    [TBL] [Abstract][Full Text] [Related]  

  • 2. N-Terminal Prosomatostatin as a Risk Marker for Cardiovascular Disease and Diabetes in a General Population.
    Hedbäck T; Almgren P; Nilsson PM; Melander O
    J Clin Endocrinol Metab; 2016 Sep; 101(9):3437-44. PubMed ID: 27399347
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The relationship between N-terminal prosomatostatin, all-cause and cardiovascular mortality in patients with type 2 diabetes mellitus (ZODIAC-35).
    van Dijk PR; Landman GW; van Essen L; Struck J; Groenier KH; Bilo HJ; Bakker SJ; Kleefstra N
    BMC Endocr Disord; 2015 Apr; 15():19. PubMed ID: 25880900
    [TBL] [Abstract][Full Text] [Related]  

  • 4. N-Terminal Prosomatostatin and Risk of Vascular Dementia.
    Holm H; Nägga K; Nilsson ED; Ricci F; Cinosi E; Melander O; Hansson O; Bachus E; Magnusson M; Fedorowski A
    Cerebrovasc Dis; 2017; 44(5-6):259-265. PubMed ID: 28854435
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Peroxiredoxin 4, a novel circulating biomarker for oxidative stress and the risk of incident cardiovascular disease and all-cause mortality.
    Abbasi A; Corpeleijn E; Postmus D; Gansevoort RT; de Jong PE; Gans RO; Struck J; Schulte J; Hillege HL; van der Harst P; Peelen LM; Beulens JW; Stolk RP; Navis G; Bakker SJ
    J Am Heart Assoc; 2012 Oct; 1(5):e002956. PubMed ID: 23316297
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vasoactive Biomarkers Associated With Long-Term Incidence of Symptomatic Peripheral Arterial Disease and Mortality.
    Dakhel A; Engström G; Melander O; Acosta S; Fatemi S; Gottsäter A; Zarrouk M
    Angiology; 2021 Jul; 72(6):550-555. PubMed ID: 33504164
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Soluble Vascular Cell Adhesion Molecules May be Protective of Future Cardiovascular Disease Risk: Findings from the PREVEND Prospective Cohort Study.
    Kunutsor SK; Bakker SJL; Dullaart RPF
    J Atheroscler Thromb; 2017 Aug; 24(8):804-818. PubMed ID: 28202840
    [TBL] [Abstract][Full Text] [Related]  

  • 8. B-type natriuretic peptides improve cardiovascular disease risk prediction in a cohort of women.
    Everett BM; Berger JS; Manson JE; Ridker PM; Cook NR
    J Am Coll Cardiol; 2014 Oct; 64(17):1789-97. PubMed ID: 25443700
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Plasma calprotectin and risk of cardiovascular disease: Findings from the PREVEND prospective cohort study.
    Kunutsor SK; Flores-Guerrero JL; Kieneker LM; Nilsen T; Hidden C; Sundrehagen E; Seidu S; Dullaart RPF; Bakker SJL
    Atherosclerosis; 2018 Aug; 275():205-213. PubMed ID: 29957458
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Usefulness of B-type Natriuretic Peptides to Predict Cardiovascular Events in Women (from the Women's Health Study).
    Everett BM; Ridker PM; Cook NR; Pradhan AD
    Am J Cardiol; 2015 Aug; 116(4):532-7. PubMed ID: 26081066
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Circulating gamma glutamyltransferase and prediction of cardiovascular disease.
    Kunutsor SK; Bakker SJ; Kootstra-Ros JE; Gansevoort RT; Dullaart RP
    Atherosclerosis; 2015 Feb; 238(2):356-64. PubMed ID: 25555268
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of midregional pro-A-type natriuretic peptide and the N-terminal pro-B-type natriuretic peptide for predicting mortality and cardiovascular events.
    van Hateren KJ; Alkhalaf A; Kleefstra N; Groenier KH; de Jong PE; de Zeeuw D; Gans RO; Struck J; Bilo HJ; Gansevoort RT; Bakker SJ
    Clin Chem; 2012 Jan; 58(1):293-7. PubMed ID: 21948291
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Galectin-3 is independently associated with cardiovascular mortality in community-dwelling older adults without known cardiovascular disease: The Rancho Bernardo Study.
    Daniels LB; Clopton P; Laughlin GA; Maisel AS; Barrett-Connor E
    Am Heart J; 2014 May; 167(5):674-82.e1. PubMed ID: 24766977
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Toe-brachial index as a predictor of cardiovascular disease and all-cause mortality in people with type 2 diabetes and microalbuminuria.
    Zobel EH; von Scholten BJ; Reinhard H; Persson F; Hansen TW; Parving HH; Jacobsen PK; Rossing P
    Diabetologia; 2017 Oct; 60(10):1883-1891. PubMed ID: 28681124
    [TBL] [Abstract][Full Text] [Related]  

  • 15. GlycA, a Pro-Inflammatory Glycoprotein Biomarker, and Incident Cardiovascular Disease: Relationship with C-Reactive Protein and Renal Function.
    Gruppen EG; Riphagen IJ; Connelly MA; Otvos JD; Bakker SJ; Dullaart RP
    PLoS One; 2015; 10(9):e0139057. PubMed ID: 26398105
    [TBL] [Abstract][Full Text] [Related]  

  • 16. ST2 may not be a useful predictor for incident cardiovascular events, heart failure and mortality.
    Hughes MF; Appelbaum S; Havulinna AS; Jagodzinski A; Zeller T; Kee F; Blankenberg S; Salomaa V;
    Heart; 2014 Nov; 100(21):1715-21. PubMed ID: 25080471
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Plasma high-sensitivity troponin T predicts end-stage renal disease and cardiovascular and all-cause mortality in patients with type 1 diabetes and diabetic nephropathy.
    Galsgaard J; Persson F; Hansen TW; Jorsal A; Tarnow L; Parving HH; Rossing P
    Kidney Int; 2017 Nov; 92(5):1242-1248. PubMed ID: 28712855
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Plasma Fibroblast Growth Factor 23: Clinical Correlates and Association With Cardiovascular Disease and Mortality in the Framingham Heart Study.
    Haring R; Enserro D; Xanthakis V; Mitchell GF; Benjamin EJ; Hamburg NM; Sullivan L; Nauck M; Wallaschofski H; Vasan RS
    J Am Heart Assoc; 2016 Jul; 5(7):. PubMed ID: 27385427
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inverse linear associations between liver aminotransferases and incident cardiovascular disease risk: The PREVEND study.
    Kunutsor SK; Bakker SJ; Kootstra-Ros JE; Blokzijl H; Gansevoort RT; Dullaart RP
    Atherosclerosis; 2015 Nov; 243(1):138-47. PubMed ID: 26386210
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serum Fractalkine (CX3CL1) and Cardiovascular Outcomes and Diabetes: Findings From the Chronic Renal Insufficiency Cohort (CRIC) Study.
    Shah R; Matthews GJ; Shah RY; McLaughlin C; Chen J; Wolman M; Master SR; Chai B; Xie D; Rader DJ; Raj DS; Mehta NN; Budoff M; Fischer MJ; Go AS; Townsend RR; He J; Kusek JW; Feldman HI; Foulkes AS; Reilly MP;
    Am J Kidney Dis; 2015 Aug; 66(2):266-73. PubMed ID: 25795074
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.